Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. (IKT)
Company Research
Source: GlobeNewswire
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that the first patient has been enrolled in the Company’s pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). “Enrollment of the first patient in our IMPROVE-PAH trial is a major milestone for Inhibikase, and the result of many months of work to optimize the IKT-001 study plan to permit a single pivotal global study and significantly accelerate the timeline to potential NDA filing,” said Mark Iwicki, Chief Executive Officer of Inhibikase. IKT-001 is a novel oral prodrug of imatinib mesylate designed to reduce gastrointestinal (“GI”) side effects commonly observed with imatinib. Under the revised pivotal Phase 3 design, as confirmed in the
Show less
Read more
Impact Snapshot
Event Time:
IKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKT alerts
High impacting Inhibikase Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IKT
News
- Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent ActivityGlobeNewswire
- Inhibikase Therapeutics (IKT) was upgraded by LADENBURG THALM/SH SH to "strong-buy".MarketBeat
- Inhibikase Therapeutics (IKT) is now covered by LADENBURG THALM/SH SH. They set a "buy" rating and a $4.00 price target on the stock.MarketBeat
IKT
Earnings
- 3/26/26 - Miss
IKT
Sec Filings
- 4/7/26 - Form 8-K
- 3/26/26 - Form S-8
- 3/26/26 - Form 10-K
- IKT's page on the SEC website